Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRYS 
Krystal Biotech Inc (KRYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KRYS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $205.2
1 Year Target Price $205.2
| 8 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.82% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.27B USD | Price to earnings Ratio 30.01 | 1Y Target Price 205.2 |
Price to earnings Ratio 30.01 | 1Y Target Price 205.2 | ||
Volume (30-day avg) 11 | Beta 0.7 | 52 Weeks Range 122.80 - 207.84 | Updated Date 08/28/2025 |
52 Weeks Range 122.80 - 207.84 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.92 |
Earnings Date
Report Date 2025-08-04 | When - | Estimate 1.22 | Actual 1.29 |
Profitability
Profit Margin 40.85% | Operating Margin (TTM) 40.93% |
Management Effectiveness
Return on Assets (TTM) 9.23% | Return on Equity (TTM) 15.61% |
Valuation
Trailing PE 30.01 | Forward PE 32.36 | Enterprise Value 3600836714 | Price to Sales(TTM) 11.9 |
Enterprise Value 3600836714 | Price to Sales(TTM) 11.9 | ||
Enterprise Value to Revenue 10.02 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 28943000 | Shares Floating 22979859 |
Shares Outstanding 28943000 | Shares Floating 22979859 | ||
Percent Insiders 11.86 | Percent Institutions 104.17 |
Upturn AI SWOT
Krystal Biotech Inc
Company Overview
History and Background
Krystal Biotech Inc. was founded in 2016. It focuses on developing and commercializing gene therapies for rare diseases. Its initial focus was on dermatological conditions. Krystal's key milestone was the FDA approval of Vyjuvek in 2023.
Core Business Areas
- Gene Therapy for Rare Diseases: Krystal Biotech develops and commercializes gene therapies for rare diseases, particularly those affecting the skin. The company utilizes its STAR-D platform for gene delivery.
Leadership and Structure
Krstal Biotech's founder and CEO is Krish S. Krishnan. The company operates with a structured management team overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Vyjuvek: Vyjuvek (beremagene geperpavec) is Krystal Biotech's lead product, an FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB). Krystal has a monopoly in this market as there are no direct competitors for DEB treatment. Revenue projections for Vyjuvek are estimated to reach several hundred million USD annually.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by technological advancements and increasing approvals of gene therapies for various diseases. The rare disease market is also expanding due to increased awareness and regulatory support.
Positioning
Krystal Biotech is a leader in developing gene therapies for rare dermatological diseases. Its competitive advantage lies in its STAR-D platform and its first-mover advantage with Vyjuvek. There is strong unmet need in rare dermatological diseases.
Total Addressable Market (TAM)
The total addressable market for DEB is estimated to be approximately $500 million to $1 billion. Krystal Biotech is well-positioned to capture a significant share of this TAM with Vyjuvek.
Upturn SWOT Analysis
Strengths
- FDA-approved gene therapy (Vyjuvek)
- Proprietary STAR-D gene delivery platform
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single product (Vyjuvek)
- High cost of gene therapy development
- Manufacturing complexity
- Dependence on market access and reimbursement
Opportunities
- Expanding indications for Vyjuvek
- Developing gene therapies for other rare diseases
- Partnering with other pharmaceutical companies
- Expanding into new geographic markets
Threats
- Competition from other gene therapy companies
- Regulatory challenges
- Manufacturing issues
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- VRTX
Competitive Landscape
Krystal Biotech has a competitive advantage in gene therapies for rare dermatological diseases, particularly with its first-mover advantage with Vyjuvek. Compared to competitors in the broader rare disease space, Krystal is smaller but focused.
Growth Trajectory and Initiatives
Historical Growth: Krystal Biotech has experienced significant growth in recent years, driven by the development and approval of Vyjuvek.
Future Projections: Analysts project significant revenue growth for Krystal Biotech in the coming years, driven by Vyjuvek sales and the potential for future product approvals.
Recent Initiatives: Recent initiatives include the commercial launch of Vyjuvek, expanding manufacturing capacity, and advancing other pipeline programs.
Summary
Krystal Biotech is a promising biotechnology company with a focus on gene therapies for rare diseases. The company's recent FDA approval of Vyjuvek is a major milestone. While Krystal Biotech faces challenges such as manufacturing complexity and market access, its strong technology platform and experienced management team position it well for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Krystal Biotech Inc. website
- SEC filings
- Analyst reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Krystal Biotech Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2017-09-20 | Founder, Chairman, President & CEO Mr. Krish S. Krishnan M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 275 | Website https://www.krystalbio.com |
Full time employees 275 | Website https://www.krystalbio.com | ||
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.